The market expects Mirum Pharmaceuticals, Inc. (MIRM) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other h ...

Group 1 - Mirum Pharmaceuticals received approval from Health Canada for the tablet formulation of Livmarli to treat cholestatic pruritus in patients with Alagille syndrome (ALGS) [1] - Following the approval announcement, Mirum's shares increased by over 5% in pre-market trading [1] - ALGS is a rare genetic disorder that can cause cholestasis and severe itching due to bile duct abnormalities [1] Group 2 - Livmarli was previously approved in Canada as an oral solution for ALGS patients aged 12 months and older [2] - Health Canada also authorized Livmarli for treating cholestatic pruritus in patients aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC) [2] - Mirum Pharmaceuticals shares closed at $103.96 on Wednesday, reflecting a decrease of 1.41% [2]

Core Insights - Three stocks in the health care sector are signaling potential warnings for momentum-focused investors as of February 2, 2026 [1] Group 1: Momentum Indicators - The Relative Strength Index (RSI) is a key momentum indicator that compares a stock's performance on days with price increases to days with price decreases, helping traders gauge short-term performance [2] - A stock is generally considered overbought when its RSI exceeds 70, indicating potential caution for investors [2] Group 2: Specific Stocks - Brookdale Senior Living Inc (NYSE:BKD) and Mirum Pharmaceuticals Inc (NASDAQ:MIRM) are highlighted as major overbought stocks in the health care sector [3] - Amicus Therapeutics has seen a significant stock price increase of approximately 139% over the past six months, with a recent RSI value of 80.4, indicating it is overbought [3] - The stock of Amicus Therapeutics closed at $14.29, slightly up by 0.1% on the last trading day, with a 52-week high of $14.38 [3]

Core Viewpoint - Mirum Pharmaceuticals is showing strong performance and growth potential, with shares more than doubling over the past year, but it is not yet consistently profitable [1][2]. Financial Performance - For the first nine months of 2025, Mirum generated $372.4 million in revenue, reflecting a year-over-year increase of 56.8% [3]. - The company reported a loss per share of $0.35 for this period, an improvement from a loss of $1.36 per share in the same period last year [3]. - In Q3 2025, Mirum achieved a net profit of $2.9 million, a significant turnaround from a net loss of $14.2 million in Q3 2024 [4]. Revenue Projections - Mirum expects to achieve $520 million in net product sales for the full 2025 fiscal year, indicating at least a 54.4% growth compared to 2024 [6]. - For 2026, the company is guiding for net sales between $630 million to $650 million, representing a midpoint growth of 23.1% compared to 2025 [6]. Strategic Acquisitions - The company recently acquired Bluejay Therapeutics for $620 million, which may negatively impact short-term profitability due to acquisition costs but is expected to enhance revenue and earnings in the long run [7]. Future Outlook - Mirum has key clinical catalysts that could positively impact its stock price and drive sales growth [8]. - Despite recent strong performance, there are concerns about limited upside potential and the timeline for achieving consistent profitability [8][9].

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is one of the 11 Best Stocks to Buy for Investment. On January 26, TheFly reported that H.C. Wainwright raised its price target on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) from $102 to $130 while maintaining its Buy rating. Swayampakula Ramakanth from H.C. Wainwright has increased the price target on MIRM twice in a span of two weeks. H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? Ramakanth’s price ta ...

Core Viewpoint - Mirum Pharmaceuticals is positioned for significant growth, with its share price having more than doubled in the past year and expectations for further increases in 2026 due to key developments in its pipeline and financial performance [1]. Financial Performance - Mirum achieved positive cash flow from operations in 2025, marking a significant milestone for the company [2]. - Net product sales for Livmarli increased by 69% year over year in 2025, reaching $359 million, while sales for Cholbam and Ctexli rose by 31% to $161 million. The company anticipates overall revenue guidance of $630 million to $650 million for the current year [5]. Regulatory Approvals - The company received two FDA approvals in the previous year: Ctexli for treating cerebrotendinous xanthomatosis and a tablet formulation of Livmarli for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis [3]. Pipeline Developments - On January 26, 2026, Mirum completed the acquisition of Bluejay Therapeutics, adding brelovitug to its pipeline, which targets chronic hepatitis delta virus, a rare liver disease with no current approved treatment in the U.S. [4]. - The company is expecting results from a Phase 2B clinical study of volixibat for primary sclerosing cholangitis in the second quarter of 2026, with plans to file for accelerated approval in the second half of the year [6]. - Results from a Phase 3 study of brelovitug for HDV treatment are anticipated in the latter half of 2026, with potential filing for approval in early 2027 if results are positive [8]. - The timing of the Phase 3 study of Livmarli for pruritus in rare cholestatic conditions has been accelerated, with enrollment expected to complete in the first half of 2026 and topline data to be reported by year-end [9].

Core Viewpoint - Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is highlighted as a promising mid-cap growth stock, with multiple analysts raising their price targets following strong preliminary earnings results and positive guidance for 2026 [1][2][3]. Analyst Ratings and Price Targets - Baird analyst Brian Skorney increased the price target for Mirum Pharmaceuticals to $95 from $81, maintaining an Outperform rating due to a beat-and-raise on earnings and guidance [1]. - H.C. Wainwright also raised its price target for Mirum Pharmaceuticals to $102 from $81, while keeping a Buy rating, citing impressive preliminary financial results and bullish guidance for 2026 [2]. - Citizens raised its price target for Mirum Pharmaceuticals to $140 from $95, maintaining an Outperform rating, and noted the company's expected leadership position in 2026, supported by pivotal readouts in its clinical pipeline [3]. Company Overview - Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapies for rare and orphan diseases [4].

Core Insights - CorMedix (CRMD) and Mirum Pharmaceuticals (MIRM) attract investors in the rare-disease biotech sector due to smaller patient populations that can yield significant revenue through premium pricing and regulatory incentives [1] - Both companies benefit from clearer clinical endpoints and faster regulatory pathways, allowing quicker market entry compared to traditional drugs [1] CorMedix (CRMD) Overview - CorMedix's lead product, DefenCath, received FDA approval in late 2023 as the first antimicrobial catheter lock solution in the U.S., aimed at reducing catheter-related bloodstream infections in kidney failure patients [2] - DefenCath generated $167.6 million in net sales in the first nine months of 2025, indicating strong market adoption [7] - The company plans to expand DefenCath's label into total parenteral nutrition and has diversified its revenue through a $300 million acquisition of Melinta Therapeutics, adding seven approved therapies to its portfolio [7] - Despite initial success, CorMedix's future outlook is cautious, with 2026 revenue guidance of $300-$320 million and projected 2027 revenues of $100-$140 million, reflecting pricing pressures and limited growth [8][11] Mirum Pharmaceuticals (MIRM) Overview - Mirum's lead product, Livmarli, is approved for treating cholestatic pruritus in patients with Alagille syndrome and has seen a 70% year-over-year increase in net sales, reaching $161.4 million in the first nine months of 2025 [3][12] - The company has expanded its portfolio with a new tablet formulation of Livmarli and additional bile acid products from the acquisition of Travere Therapeutics, generating $118.8 million in the first nine months of 2025 [16] - MIRM's revenue guidance for 2026 is approximately $630-$650 million, supported by a broader product base and ongoing clinical studies for new therapies [16][28] Comparative Analysis - Both companies exhibit a similar risk-reward profile, but MIRM presents a clearer growth narrative with multiple revenue drivers, while CRMD's outlook is clouded by conservative guidance and reliance on a single product [4][9] - MIRM's shares have increased by 75.3% over the past six months, contrasting with CRMD's 38% decline, indicating market preference for MIRM's growth potential [23] - Valuation metrics show MIRM trading at a price/book ratio of 16.02, significantly higher than CRMD's 1.43, reflecting investor confidence in MIRM's growth prospects [24] Investment Recommendation - Mirum Pharmaceuticals is viewed as the better investment opportunity due to its strong sales growth, diversified revenue streams, and multiple growth levers, while CorMedix faces more uncertainty and competitive pressures [25][29]

Core Insights - Mirum Pharmaceuticals (MIRM) shares increased by 7.1% following the announcement of strong preliminary results for Q4 and full-year 2025, which boosted investor confidence [1][6] Financial Performance - Preliminary net product sales for Mirum in 2025 were approximately $520 million, exceeding the management's guidance of $500-$510 million provided in November 2025 [2][6] - Estimated net product sales for Livmarli were around $359 million for 2025, while Cholbam and Ctexli contributed approximately $161 million [4] - For Q4 2025, estimated net product sales were about $149 million, including $106 million from Livmarli and around $43 million from Cholbam and Ctexli [5] 2026 Sales Outlook - Mirum forecasts net product sales of approximately $630-$650 million for 2026 [6][7] - The company is conducting a phase III study for Livmarli aimed at treating pruritus in rare cholestatic conditions, with enrollment expected to complete in the first half of 2026 [7] Pipeline Developments - Mirum's lead pipeline candidate, volixibat, is under evaluation in two phase IIb studies for primary biliary cholangitis and primary sclerosing cholangitis, with top-line data from the VISTAS study anticipated in Q2 2026 [8] - A definitive agreement to acquire Bluejay Therapeutics was announced in December 2025, which will enhance Mirum's portfolio in rare liver diseases [9] - A phase II study has been initiated for MRM-3379, a PDE4D inhibitor targeting Fragile X syndrome [10]

Company Overview - Mirum is a rare disease company focused on delivering life-changing medicines to patients with rare diseases [2] - The company is entering a pivotal year with strong commercial performance anticipated [2] Financial Performance - For the year, Mirum announced an estimated total product revenue of $520 million [2] - Guidance for 2026 is projected to be between $630 million and $650 million [2]